MX2017017051A - Composiciones y métodos relacionados con partículas depuradoras. - Google Patents
Composiciones y métodos relacionados con partículas depuradoras.Info
- Publication number
- MX2017017051A MX2017017051A MX2017017051A MX2017017051A MX2017017051A MX 2017017051 A MX2017017051 A MX 2017017051A MX 2017017051 A MX2017017051 A MX 2017017051A MX 2017017051 A MX2017017051 A MX 2017017051A MX 2017017051 A MX2017017051 A MX 2017017051A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- particles
- scavanger
- methods related
- pathogen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente invención se refiere, entre otras cosas, a composiciones que se unen a, e inhiben la actividad biológica de biomoléculas solubles, así como también a composiciones farmacéuticas de la misma. Las composiciones pueden comprender una pluralidad de partículas que se unen específicamente a un objetivo, tal como una biomolécula soluble o una biomolécula en la superficie de un patógeno, para inhibir el objetivo (o patógeno) de interactuar con otras moléculas o células. También se proporcionan en la presente un número de aplicaciones (por ejemplo, aplicaciones terapéuticas) en las cuales las composiciones son útiles.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186838P | 2015-06-30 | 2015-06-30 | |
US201562198519P | 2015-07-29 | 2015-07-29 | |
US201562198541P | 2015-07-29 | 2015-07-29 | |
US201562236507P | 2015-10-02 | 2015-10-02 | |
US201662319092P | 2016-04-06 | 2016-04-06 | |
PCT/US2016/040022 WO2017004159A1 (en) | 2015-06-30 | 2016-06-29 | Compositions and methods related to scavanger particles |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017017051A true MX2017017051A (es) | 2018-05-15 |
Family
ID=57609422
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017017051A MX2017017051A (es) | 2015-06-30 | 2016-06-29 | Composiciones y métodos relacionados con partículas depuradoras. |
MX2023005261A MX2023005261A (es) | 2015-06-30 | 2017-12-20 | Composiciones y metodos relacionados con particulas depuradoras. |
MX2023005262A MX2023005262A (es) | 2015-06-30 | 2017-12-20 | Composiciones y metodos relacionados con particulas depuradoras. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023005261A MX2023005261A (es) | 2015-06-30 | 2017-12-20 | Composiciones y metodos relacionados con particulas depuradoras. |
MX2023005262A MX2023005262A (es) | 2015-06-30 | 2017-12-20 | Composiciones y metodos relacionados con particulas depuradoras. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180256747A1 (es) |
EP (1) | EP3316864A4 (es) |
JP (3) | JP7370691B2 (es) |
KR (1) | KR20180043785A (es) |
CN (4) | CN108135848A (es) |
AU (2) | AU2016285868B2 (es) |
BR (1) | BR112017028315A2 (es) |
CA (1) | CA2991142A1 (es) |
EA (1) | EA201890170A1 (es) |
HK (1) | HK1255328A1 (es) |
IL (2) | IL256445B2 (es) |
MX (3) | MX2017017051A (es) |
MY (1) | MY198240A (es) |
SG (1) | SG10201913518XA (es) |
WO (1) | WO2017004159A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107837389B (zh) | 2014-10-03 | 2022-12-13 | 纳米提克斯有限责任公司 | 用于抑制可溶生物分子的生物活性的组合物以及方法 |
EA201890391A1 (ru) | 2015-07-29 | 2018-08-31 | НАНОТИКС, ЭлЭлСи | Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы |
WO2017136356A2 (en) * | 2016-02-01 | 2017-08-10 | Emory University | Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
EP3565604A4 (en) * | 2017-01-04 | 2020-09-09 | Nanotics, LLC | ELIMINATING PARTICLE ASSEMBLY PROCESSES |
KR20190129077A (ko) | 2017-03-15 | 2019-11-19 | 팬디온 테라퓨틱스, 인코포레이티드 | 표적화된 면역관용 |
MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
CN113893328A (zh) * | 2017-06-14 | 2022-01-07 | 天津医科大学总医院 | 一种人源乳凝集素亚型蛋白的新用途 |
EP3477305A1 (en) | 2017-10-25 | 2019-05-01 | Universität Heidelberg | Delta-like ligand 1 for diagnosing severe infections |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
FR3094268B1 (fr) * | 2019-03-28 | 2021-03-19 | Carbiolice | Article multicouche enzymé |
US20220202716A1 (en) * | 2019-04-15 | 2022-06-30 | Nanologica Ab | Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia |
JP2022533702A (ja) | 2019-05-20 | 2022-07-25 | パンディオン・オペレーションズ・インコーポレイテッド | MAdCAM標的化免疫寛容 |
JP2022537807A (ja) * | 2019-06-21 | 2022-08-30 | エンテレクソ バイオセラピューティクス インク. | 治療送達用のプラットフォーム、組成物、および方法 |
WO2021231436A1 (en) * | 2020-05-11 | 2021-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic methods for treating covid-19 infections |
CN111575388B (zh) * | 2020-06-02 | 2022-10-21 | 江汉大学 | PfHMGB1作为藻毒素侵害的分子标志物的应用及检测试剂盒 |
CN112264115B (zh) * | 2020-10-26 | 2022-03-11 | 南京鼓楼医院 | 一种搭载分子印迹反蛋白石结构微球的鱼骨微流控芯片及其制备方法 |
CN113358617B (zh) * | 2021-06-02 | 2024-03-01 | 重庆大学 | 胞外囊泡富集检测方法 |
KR20230023442A (ko) | 2021-08-10 | 2023-02-17 | 현대자동차주식회사 | 차량의 차체 |
CN114128723B (zh) * | 2021-11-09 | 2023-07-04 | 苏州大学 | 一种抗病毒纳米材料及其应用 |
JP7368766B2 (ja) | 2022-03-02 | 2023-10-25 | 株式会社リコー | 情報処理装置、情報処理システム、情報処理方法およびプログラム |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
CN101123990A (zh) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒,和免疫原性结构 |
US20070248680A1 (en) * | 2005-02-08 | 2007-10-25 | Board Of Regents, The University Of Texas System | Particles for Inactivating Toxins |
EP2033660A1 (en) | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
WO2010042555A2 (en) * | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
US20120108787A1 (en) * | 2009-02-26 | 2012-05-03 | Nubiome, Inc. | Immobilization Particles for Removal of Microorganisms and/or Chemicals |
CN103857387B (zh) | 2011-06-02 | 2017-03-15 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
WO2013030831A2 (en) * | 2011-08-26 | 2013-03-07 | Vecoy Nanomedicines Ltd. | Pathogen and substance traps |
WO2014109842A2 (en) * | 2012-11-28 | 2014-07-17 | Cytimmune Sciences, Inc. | Nanotechnology based medicine for biodefense |
US20170038382A1 (en) * | 2014-01-24 | 2017-02-09 | Ntercept, Llc | Methods and compositions for immune dis-inhibition |
CN107837389B (zh) | 2014-10-03 | 2022-12-13 | 纳米提克斯有限责任公司 | 用于抑制可溶生物分子的生物活性的组合物以及方法 |
-
2016
- 2016-06-29 AU AU2016285868A patent/AU2016285868B2/en active Active
- 2016-06-29 CA CA2991142A patent/CA2991142A1/en active Pending
- 2016-06-29 JP JP2017568165A patent/JP7370691B2/ja active Active
- 2016-06-29 CN CN201680049849.5A patent/CN108135848A/zh active Pending
- 2016-06-29 BR BR112017028315A patent/BR112017028315A2/pt active Search and Examination
- 2016-06-29 IL IL256445A patent/IL256445B2/en unknown
- 2016-06-29 KR KR1020187002793A patent/KR20180043785A/ko not_active Application Discontinuation
- 2016-06-29 MY MYPI2017001935A patent/MY198240A/en unknown
- 2016-06-29 SG SG10201913518XA patent/SG10201913518XA/en unknown
- 2016-06-29 WO PCT/US2016/040022 patent/WO2017004159A1/en active Application Filing
- 2016-06-29 EP EP16818651.8A patent/EP3316864A4/en active Pending
- 2016-06-29 US US15/738,954 patent/US20180256747A1/en active Pending
- 2016-06-29 CN CN202111385729.1A patent/CN114129737A/zh active Pending
- 2016-06-29 CN CN202310865497.2A patent/CN116785457A/zh active Pending
- 2016-06-29 MX MX2017017051A patent/MX2017017051A/es unknown
- 2016-06-29 IL IL297460A patent/IL297460A/en unknown
- 2016-06-29 CN CN202310869623.1A patent/CN116763941A/zh active Pending
- 2016-06-29 EA EA201890170A patent/EA201890170A1/ru unknown
-
2017
- 2017-12-20 MX MX2023005261A patent/MX2023005261A/es unknown
- 2017-12-20 MX MX2023005262A patent/MX2023005262A/es unknown
-
2018
- 2018-11-13 HK HK18114464.8A patent/HK1255328A1/zh unknown
-
2021
- 2021-10-29 JP JP2021177516A patent/JP2022031665A/ja not_active Withdrawn
-
2022
- 2022-01-14 AU AU2022200233A patent/AU2022200233A1/en active Pending
-
2023
- 2023-07-13 JP JP2023114971A patent/JP2023153813A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116763941A (zh) | 2023-09-19 |
JP2022031665A (ja) | 2022-02-22 |
BR112017028315A2 (pt) | 2018-09-04 |
MX2023005261A (es) | 2023-05-23 |
IL256445A (en) | 2018-04-30 |
AU2022200233A1 (en) | 2022-02-10 |
CN114129737A (zh) | 2022-03-04 |
AU2016285868B2 (en) | 2021-11-11 |
EP3316864A4 (en) | 2019-03-06 |
KR20180043785A (ko) | 2018-04-30 |
MY198240A (en) | 2023-08-16 |
CN116785457A (zh) | 2023-09-22 |
IL256445B (en) | 2022-11-01 |
MX2023005262A (es) | 2023-05-23 |
IL297460A (en) | 2022-12-01 |
JP2023153813A (ja) | 2023-10-18 |
HK1255328A1 (zh) | 2019-08-16 |
JP2018524344A (ja) | 2018-08-30 |
JP7370691B2 (ja) | 2023-10-30 |
CN108135848A (zh) | 2018-06-08 |
SG10201913518XA (en) | 2020-02-27 |
WO2017004159A1 (en) | 2017-01-05 |
US20180256747A1 (en) | 2018-09-13 |
EP3316864A1 (en) | 2018-05-09 |
IL256445B2 (en) | 2023-03-01 |
EA201890170A1 (ru) | 2018-07-31 |
CA2991142A1 (en) | 2017-01-05 |
AU2016285868A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023005261A (es) | Composiciones y metodos relacionados con particulas depuradoras. | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
MX2022001222A (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos. | |
EA201890391A1 (ru) | Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы | |
EA201890630A1 (ru) | Антитела против pd-1 и способы их применения | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
PH12016502505A1 (en) | Bispecific t cell activating antigen binding molecules | |
BR112019011582A2 (pt) | anticorpos e métodos de utilização dos mesmos | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
AU2015329974A8 (en) | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use | |
MY184889A (en) | T cell activating bispecific antigen binding molecules | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
WO2015109124A3 (en) | Immunomodulatory agents | |
NZ730450A (en) | Binding molecules, especially antibodies, binding to l1cam (cd171) | |
AR108180A1 (es) | Partículas que comprenden subpartículas o estructuras de ácidos nucleicos | |
EA201790505A1 (ru) | Соединение, нацеленое на ил-23а и фно-альфа, и его применение | |
WO2015058861A8 (en) | Bispecific constructs and their use in the treatment of various diseases | |
WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
WO2017205852A3 (en) | Protein interfaces | |
MX2021001418A (es) | Produccion de proteinas heteromultimericas usando celulas de mamifero. | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
MX2015014198A (es) | Anticuerpos cuyo objetivo es m-csf. | |
WO2015160928A3 (en) | Isolated t cell receptors and methods of use therefor |